Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD5055 in Healthy Volunteers
NCT05134727Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD5055 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AEs). Started Nov 2021; status: completed.
02
Drugs
AZD5055
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05134727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134727.